Tollys
Tollys is a biopharmaceutical company focused on innate immunity, particularly on the biology and modulation of the TLR3 receptor.
Tollys has raised €2.3M across 1 funding round, most recently a Series A round in May 2020. Based in Lyon, France; founded 2015; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€2.3M
€2,300,000
Funding rounds
1
Investors
0
distinct backers
Active since
2020-05
latest 2020-05
Funding by year
EUR raised per yearTollys — funding by year — interactive chart.
Data table
| Tollys — funding by year | |
|---|---|
| 2020 | €2.3M |
Signals
Medium confidenceRaise-next likelihood9
base rate 44% for Series A
- ▼ Dormant (no round in 3+ cohort gaps)
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-05-26 | Series A | €2.3M | — | View deal → |
Related news
Similar companies
same sector or country- Mistral AI€6.5BFrance · AI
- Automotive Cells Company (ACC)€4.4BFrance · Transportation
- Philips€2.6BNetherlands · Healthtech
- Verkor€2.4BFrance · Energy
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
Global coverage: FundingData